What is myPath® Melanoma?
Melanoma is a potentially fatal form of skin cancer. Early & accurate diagnosis is critical for long-term survival. 1
The analysis of biopsied tissue using a microscope (histopathology) has long been the standard of care for melanoma diagnosis. While it is adequate for diagnosis in most cases, evidence suggests that approximately 10-15% of biopsied melanocytic lesions may be histopathologically ambiguous.2-5 In these situations, microscopic examination may reveal a few features that are characteristic of melanoma but others that are more typical of a benign nevus (‘mole’). As a result, even experienced dermatopathologists occasionally disagree as to whether a given melanocytic lesion is benign or malignant.
Myriad Genetic Laboratories
Myriad Genetic Laboratories has developed myPath® Melanoma, a clinically validated test to be used as an adjunct to histopathology when the distinction between a benign nevus and a malignant melanoma cannot be made confidently by histopathology alone.
The test measures the expression of 23 genes by qRT-PCR methodology and distinguishes melanoma from nevi with a sensitivity of 90-94% and a specificity of 91-96%. 7,29,30
90% - 94%
91% - 96%
How the myPath Melanoma Test Works
The myPath Melanoma test measures 23 genes for which expression patterns differ between malignant melanoma and benign nevi. These genes are involved in cell differentiation, cell signaling, and immune response signaling.
The genes include:
- PRAME a single gene involved in cell differentiation
- S100A7, S100A8, S100A9, S100A12 and PI3, a group of genes involved in multiple cell signaling pathways
- CCL5, CD38, CXCL10, CXCL9, IRF1, LCP2, PTPRC and SELL involved in tumor immune response signaling
- Nine reference genes that are measured to normalize RNA expression for analysis
Reference genes included: CLTC, MRFAPI, PPP2CA, PSMA1, RPL13A, RPL8, RPS29, SLC25A3, and TXNLI
The result is a single numerical score
The result is a single numerical score that classifies a melanocytic lesion as ‘likely benign’, ‘likely malignant’, or ‘indeterminate’.